T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance.
Ontology highlight
ABSTRACT: We report here the clinical course of a Ph+ ALL patient who was treated with ponatinib 15 mg/day, as maintenance therapy, and developed a BCR-ABL T315I mutation leading to ALL relapse. This clonal evolution was reversed, without adverse effects, by increasing ponatinib to 45 mg/day. To our knowledge, we have been confronted with the first clinical case of a T315I clonal selection of ALL caused by subeffective therapeutic level of the drug. This single patient experience highlights the risk of T315I clone selection in Ph+ ALL treated with reduced dose ponatinib.
SUBMITTER: Noetzli J
PROVIDER: S-EPMC5538043 | biostudies-other | 2017 Aug
REPOSITORIES: biostudies-other
ACCESS DATA